Factor VIII-Fc Activates Natural Killer Cells via Fc-Mediated Interactions With CD16

The most challenging complication associated with Factor VIII (FVIII) replacement therapy is the development of neutralizing anti-drug antibodies, or inhibitors, which occur in 23-35% of severe (FVIII level <1%) hemophilia A (HA) patients and are a serious hindrance to effective management of HA....

Descripción completa

Detalles Bibliográficos
Autores principales: Lagassé, H.A. Daniel, Hopkins, Louis B., Jankowski, Wojciech, Jacquemin, Marc G., Sauna, Zuben E., Golding, Basil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273617/
https://www.ncbi.nlm.nih.gov/pubmed/34262568
http://dx.doi.org/10.3389/fimmu.2021.692157

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273617/
https://www.ncbi.nlm.nih.gov/pubmed/34262568
http://dx.doi.org/10.3389/fimmu.2021.692157

Ejemplares similares